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ABSTRACT
Introduction: Malaysia has a high rate of smoking 
prevalence and the figure is increasing. Although 
there has been many local and regional studies on 
the prevalence and symptomatology of chronic 
obstructive pulmonary disease patients, data is 
lacking on the degree of compliance to national 
management guidelines in the treatment of 
chronic obstructive pulmonary disease.
Methods :  86 patients who attended the 
respiratory outpatient clinic of the Hospital 
Universiti Kebangsaan Malaysia were enrolled 
into a prospective, observational study. 
Results:  88 percent of the patients were male 
and the majority was ethnically Chinese (65 
percent). The majority of patients were in the 
moderate to very severe categories, with a mean 
FEV1 of 0.97 +/− 0.56 L/sec and predicted mean 
FEV1 percentage of 43.1 +/− 21.3 percent. 58 
percent of the patients were on long-acting beta-
agonist, 65 percent were on inhaled steroids, and 
only 16 percent were on scheduled pulmonary 
rehabilitation.
Conclusion:  The low uptake rate for long-acting 
beta-agonist and pulmonary rehabilitation could 
be attributed to several factors. Financial cost, 
the need for strict compliance to a structured 
rehabilitation regime, lack of significant social 
support and clear up-to-date guidelines are 
possible reasons.   
Keywords : chronic obstructive pulmonary 
disease, lung disease, management guidelines, 
patient compliance, pulmonary rehabilitation
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InTRodUCTIon
Chronic obstructive pulmonary disease (COPD) is a 
growing problem worldwide. It is a progressive illness 
with considerable morbidity and mortality. Most COPD 
patients are current or ex-smokers, and countries with a 
higher prevalence of smokers in their adult population 
also register a higher prevalence of COPD.(1) In Malaysia, 
the overall smoking prevalence is 49.2% in the adult male 
population, and 3.5% in the adult female population.(2) 
Indications point toward an increasing trend in the 
prevalence of smoking with a veritable doubling of the 
prevalence of adult female smokers to 8% since the last 
National Health and Morbidity Survey by the Ministry of 
Health Malaysia in 1996.(3) 
 COPD is the sixth leading cause of death worldwide 
and the fourth leading cause of hospital admissions in 
Malaysia.(4) With the rise in smoking prevalence, there 
will be an inevitable rise in COPD incidence and hence 
result in a greater strain on the already stretched resources, 
especially in developing countries with limited health 
expenditures, like Malaysia. Furthermore, most patients 
with COPD present to doctors with moderate to severe 
disease, thereby limiting the efficacy of intervention and 
increasing the cost of symptom control in these patients.(2) 
Treatment efficacy may also be influenced by the degree 
of compliance with the various management guidelines 
and patient compliance to treatment.
 Although there has been many local and regional 
studies on the prevalence and symptomatology of COPD 
among the Malaysian population, no study has actually 
looked at the degree of compliance to management 
guidelines be it local or international.(1,2,5,6) This study is 
aimed at assessing the severity of COPD cases presented to 
a local tertiary referral centre and the degree of compliance 
to existing national guidelines on the management of 
COPD in these patients.   
METHodS
Consecutive COPD patients, who attended the Respiratory 
Outpatient Clinic at the Hospital Universiti Kebangsaan 
Malaysia (HUKM) from October 2005 to January 2006, 
were recruited into the study. A review of the case records 
and medications was undertaken for each patient. The 
study protocol was approved by the medical research and 
ethics committee of the institution, and written informed 
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consents were obtained from the subjects.
 Inclusion criteria consisted of:
(1) Patients aged 45–95 years, of an ethnicity satisfying  
 the definition of COPD according to global initiative  
 for chronic obstructive lung disease (GOLD) 
 guidelines.(7)  
(2) Forced expiratory volume in one second (FEV1) 
 to forced vital capacity ratio (FVC) ratio < 70%, and  
 increase in FEV1 30 minutes after inhalation of a 
 β2-agonist (salbutamol)  < 15% or 200 ml.
(3) Patients must be able to complete the six-minute 
 walk test without assistance.
(4) Patients must be able to comprehend instructions 
 and questions in English and Malay.
Exclusion criteria were:
(1) Patients with multiple comorbidities limiting 
 independent ambulation, such as congestive cardiac 
 failure with New York Heart Association (NYHA) 
 class ≥ 1, ischaemic heart disease with angina  and a  
 Canadian Cardiac Society (CCS) classification for  
 angina class ≥ 1.
(2) Patients who require assistance with ambulation 
 other than a walking aid.
(3) Other concurrent pulmonary diseases, such as 
 localised bronchiectasis, pulmonary fibrosis and 
 asthma.
(4) Patients with terminal disease.
 The St. George’s Respiratory Questionnaire (SGRQ) 
is designed to measure health impairment in patients 
with asthma and COPD. The SGRQ is a self-reported 
questionnaire that can be completed in approximately 
ten minutes. The questionnaire consists of 16 questions 
divided into two parts. Part I (Questions 1 to 8) yields the 
Symptom score; this surveys the patients’ recollection of 
their symptoms over a stipulated period. Part II (Questions 
9 to 16) yields the Activity and Impact scores that survey 
the disturbance to the patients’ daily physical activity and 
psychosocial dysfunction, respectively. A total score is also 
produced and it incorporates scores from each component 
of the SGRQ.(8) Specific questions carry varying weights, 
with lower scores on the SGRQ indicating wellness, and 
higher scores indicating greater disability. The SGRQ 
has been validated in many studies and its use in many 
different languages.(9) This study used the SGRQ in both 
the English and Malay languages (Appendices 1 and 
2). Written permission was obtained for the use of the 
questionnaires. Patients were required to complete the 
SGRQ while awaiting consultation, following which they 
then performed the simple spirometry and six-minute walk 
test.
 Simple spirometry was carried out after the 
administration of the SGRQ. The post-bronchodilator (30 
minutes after inhaled salbutamol), FEV1, FVC and the peak 
expiratory flow rate were recorded using the Spiroanalyser 
ST-95. Postbronchodilator FEV1 and the calculated FEV1 
percentage predicted (FEV1%Pred) (calculated Asian 
values based on the Fukuda Sangyo Manual) were used 
Table I. Summary of measurements.
Variables	 Mean	(±	SD)
Age	(years)	 67.7	(±	8.6)
6MWD	(m)	 	321	(±	87)
FEV1	(L)
				 Total		(n	=	86)	 0.97	(±	0.56)
				 Stage	I	(n	=	5)	 2.18	(±	0.29)
				 Stage	II	(n	=	22)	 1.48	(±	0.42)
				 Stage	III	(n	=	29)	 0.86	(±	0.23)
				 Stage	IV	(n	=	30)	 0.50	(±	0.14)
FEV1%Pred	(%)	 43.1	(±	21.3)
SGRQ	scores
							Symptom	 50.2	(±	23.2)
							Impact	 35.2	(±	23.8)
						Activity	 55.1	(±	27.9)
							Total	 43.7	(±	23.6)
6MWD:	 6-minute	 walking	 distance;	 FEV1:	 forced	 expiratory	
volume	 in	 1	 second;	 SGRQ:	 St	 George’s	 Respiratory	
Questionnaire
Fig. 1	Bar	chart	shows	the	mean	FEV1	at	each	stage	of	COPD.
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Fig. 2	Bar	chart	shows	the	mean	6MWD	at	each	stage	of	COPD.
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for the classification of severity of COPD according to the 
GOLD guidelines:(7) 
Stage I: Mild COPD    FEV1 ≥ 80% predicted
Stage II: Moderate COPD   50% ≤ FEV11 < 80%  
  predicted
Stage III: Severe COPD 30% ≤ FEV1 < 50%  
  predicted
Stage IV: Very severe COPD FEV1 < 30% predicted 
  or FEV1 < 50%  
  predicted plus chronic 
  respiratory failure
 The six-minute walk test is an index of functional 
capacity, and patients were required to walk as far as 
possible in six minutes at their own pace. This was adopted 
to better reflect the patients’ daily activities.(10,11) The 
test was performed along a continuous hospital corridor 
adjacent to the respiratory function laboratory. Patients 
underwent two six-minute walk tests at least 30 minutes 
apart. The distance in metres was then recorded.
 Data for continuous, closely symmetrical variables 
were analysed using standard descriptive methods to 
estimate mean ± standard deviation (SD). To compare the 
relative performance of quality of life (QOL) measures 
in relation to the physiological measures, we utilised the 
two-tailed Pearson product moment correlation coefficient 
with the level of statistical significance set at p < 0.05. 
Comparison of means between patients with or without 
specific treatment modalities was also tested by utilising 
the independent sample t-test. The statistical software 
package, Statistical Package for Social Sciences version 
11.5 (SPSS Inc, Chicago, IL, USA), was used to perform 
the analysis.
RESULTS 
A total of 86 patients with COPD were recruited into the 
study from October 2005 to January 2006, of which 88% 
(76) were male. 65% (56/86) of the patients were Chinese, 
29% (25/86) Malay and 6% (5/86) Indian. The majority 
of the subjects were Chinese, in contrast to the normal 
population ratio. This could be attributed to the location 
of the hospital in the southeast region of Kuala Lumpur, 
which is predominantly inhabited by the Chinese. The 
mean age was 67.7 ± 8.6 years and the mean FEV1 was 
0.97 ± 0.56 L/sec (Table I). Majority of the patients who 
attended the respiratory outpatient clinic had moderate 
to severe disease with a mean FEV1%Pred of 43.1% ± 
21.3%. The COPD was mild in five patients, moderate in 
22 patients, severe in 29 patients, and very severe in 30 
patients.  The mean six-minute walk distance was 321 ± 
87 metres.  
 The most reproducible, discriminatory and useful 
physiological measurements of airflow limitation are 
FEV1, FVC and their ratio.  Fig. 1 shows the mean values 
of FEV1 for each stage of the disease as defined by the 
FEV1%Pred according to the GOLD staging system.(7) 
There were only five patients with mild COPD.  
 Objective estimates of the functional capacity can be 
provided by exercise tests, such as the six-minute walk. 
In our study, there was a significant difference in exercise 
capacity between stages 3 and 4 (Fig. 2).  There was no 
significant difference in the exercise capacity between 
patients with mild, moderate and severe COPD.  COPD 
does not only involve the lungs, but it has other systemic 
effects, which could also contribute to the symptoms, 
Table II. Pearson product moment correlation coeffi-
cient of all variables.
	
	 	 Pearson’s	correlation,	r	 p-value
FEV1	vs.		SGRQ	score	 −0.464	 <	0.001
FEV1	vs.	6MWD	 0.351	 0.001
FEV1%Pred	vs.	6MWD	 0.186	 0.086
FEV1%Pred	vs.	SGRQ	score	 −0.293	 0.006
6MWD	vs.	total	score	 −0.483	 <	0.001
6MWD:	6-minute	walking	distance;	FEV1:	forced	expiratory	vol-
ume	in	1	second;	SGRQ:	St	George’s	Respiratory	Questionnaire
Fig. 3	Bar	chart	shows	the	mean	SGRQ	total	score	at	each	stage	
of	COPD.
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Fig. 4	Bar	chart	shows	the	mean	FEV1	in	patients	with/without	
LABA.
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morbidity and mortality.  Spirometry alone could not 
explain the extrapulmonary effects of COPD.  Health-
related QOL outcomes were clinically more relevant to 
patients and provide comprehensive assessment of all 
aspects of COPD.  Again, there was only a significant 
difference in SGRQ scores between stages 3 and 4 (Fig. 
3), but not between mild and moderate COPD.
 However, when the Pearson product moment 
correlation coefficient was employed to test the correlation 
between these variables, they were all found to be mildly 
to moderately significant, albeit at varying degrees. This is 
clearly shown in Table II. Finally, we analysed the ongoing 
treatment received by the patients at the time of attendance 
and looked at whether there was any association between 
the treatment and the variables measured.
 The analysis on medications showed that 58% 
patients were on long-acting β2-agonist (LABA), 65% 
were on inhaled steroids and only 16% were on pulmonary 
rehabilitation. Patients who were on LABA had a higher 
SGRQ total score (greater debility) with a mean difference 
of 17.27 ± 4.81 (p = 0.001). Accordingly, they also fared 
worse in the six-minute walk test compared to those who 
were not on LABA, with a mean difference of 32.68 ± 
18.8 m (p = 0.086) (Table III). This pattern suggested that 
patients who had worse symptoms and exercise tolerance 
were more likely to be on LABA. This was also reflected 
in their FEV1 values (Fig. 4).
 Patients who were on steroids also showed a similar 
pattern with those who were on scoring worse (higher) 
on the SGRQ score (mean difference 15.5 ± 5.0, p = 
0.003) and the six-minute walk (mean difference of 15.3 
± 19.7, p = 0.437). In both instances, the difference in 
the six-minute walk distances between those who were 
with/without LABA and steroids did not reach statistical 
significance (Fig. 5). Interestingly, although not many 
patients were on pulmonary rehabilitation, those who 
were, displayed a trend towards better SGRQ scores 
(lower) and greater exercise tolerance, though this was 
statistically not significant. The FEV1 score also did not 
show any significant difference (Fig. 6).This again is in 
keeping with findings of other studies.
dISCUSSIon
Before discussing the findings of the study, it is worth 
pointing out that the majority of patients enrolled in this 
study had moderate to severe airflow limitation, with a 
mean FEV1 and FEV1%Pred of 0.97 ± 0.56 L/sec and 
43.1% ± 21.3%, respectively. Only five of those included 
Table III. Comparison of total SGRQ score and 6MWd between those with and without treatment.
	
	 	 With	treatment	 Without	treatment	 	p-value	 Mean	difference
LABA
	 Total	SGRQ	score	 52	 34	 0.001	 17.3	±	4.8
	 6MWD	(m)	 307.69	 340.38	 0.086	 32.68	±	18.8
Steroid
	 Total	SGRQ	score	 50	 34	 0.003	 15.5	±	5.0
	 6MWD	(m)	 316.22	 331.58	 0.437	 15.3	±	19.7
Pulmonary	rehabilitation
	 Total	SGRQ	score	 38	 45	 0.417	 5.8	±	7.1
	 6MWD	(m)	 344.01	 317.81	 0.322	 26.2	±	26.3
Fig. 5	Bar	chart	shows	the	mean	FEV1	in	patients	with/without	
steroids.
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in the study were in stage 1 of the disease (GOLD, COPD 
stage)(7) or had an FEV1%Pred of more than 80%. This 
over-representation in the more severe spectrum of 
COPD is reflective of the institution’s role as a tertiary 
referral centre and the fact that most patients present at an 
already late stage of their disease.(2) Furthermore, the over-
representation of ethnic Chinese minority in the study also 
reflects the geographical location of the institution and 
the area from which a majority of the patients are pooled 
from. It does not in any way suggest that most smokers 
in Malaysia are of Chinese ethnicity and that they have a 
moderate to severe airflow limitation. They do, however, 
influence the interpretation of any analysis made or any 
conclusions inferred from the data, and as such represent 
biases that will need to be accounted for should similar 
studies be contemplated in future.
 The Malaysia Thoracic Society management 
guidelines for COPD outlined a simple stepwise 
management plan consisting of three steps. Step I involves 
patients with mild to moderate continuing symptoms 
and the recommended pharmacological intervention is 
combined inhaled ß2-agonist and anticholinergics. The 
compliance rate at this stage is 100% as all patients who 
attended the respiratory outpatient clinic at HUKM were 
on combivent (salbutamol with ipratropium bromide) 
metred-dose inhalers. Step 2 involves the addition of 
methylxanthines in sustained release preparations. The 
use of LABAs was listed as optional, as at the time of 
its publication in 1999 the data on LABA was thought to 
be inconclusive.(6) This is in contrast to the GOLD 2006 
guidelines for the management of COPD recommendation, 
that LABA be added at Stage II (moderate) of the disease, 
citing it as having a Level A evidence.(7) This discrepancy 
in the national and international guidelines on COPD 
management may explain the low take-up rate of only 58% 
for LABA, despite the fact that 94% of the patients studied 
were eligible for it. Step 3 involves the addition of oral 
steroids in a tapering dose and its subsequent replacement 
with inhaled steroids. GOLD 2006 guidelines proposed the 
use of inhaled steroids in patients with Stage III (severe) 
disease. 68% of patients studied were within this stage and 
the take-up rate for inhaled steroids reflects the agreement 
between the national and international guidelines, as 
65% of them were on inhaled steroids. Interestingly, 
those who were on LABA and inhaled steroids scored 
significantly worse in their SGRQ scores and six-minute 
walking distance compared to those who were not. This is 
inconsistent with findings from other studies.(12-15) 
 This is an example of the weakness of cross-
sectional observation studies in detecting the benefit or 
advantage from an intervention that is better observed in a 
longitudinal study.  It most likely reflects the fact that most 
patients who were on either LABA or inhaled steroids, 
were on it due to the severity of their symptoms. The 
results in the observation revealed that their SGRQ scores 
and six-minute walk distances were worse compared 
to those who were not on this treatment, although the 
difference did not reach statistical significance. Another 
interesting observation made is the poor take-up of 
pulmonary rehabilitation of only 16% among the study 
cohort. This is again contrary to current international 
guidelines and literature. One reason may be found in the 
national guideline statement in 1999 that “there are no 
prospective randomised controlled studies that provide 
conclusive evidence of survival benefits”.(6) 
 We do believe, however, that the major hindrance 
to its uptake is the significant investment in time and 
effort that is required of patients in order to successfully 
implement pulmonary rehabilitation. Compliance to 
such a structured programme is also suspect, considering 
the severe symptoms among our patient cohort and the 
lack of any significant social support programmes for 
COPD in general. Even under the best of circumstances 
in Western centres, the refusal rate can be as high as 
30%.(16) Studies in pulmonary rehabilitation as early as 
1990, have shown improvement in both the QOL scores 
and exercise tolerance following rehabilitation.(17,18) The 
resultant lack of any statistical difference in the SGRQ 
score and six-minute walk distance between those who 
were with/without pulmonary rehabilitation is not 
surprising considering the low take-up rate for pulmonary 
rehabilitation. 
 Although not statistically significant, the results 
did show a trend towards better SGRQ scores and six-
minute walk distances. However, only 16% of patients 
were on pulmonary rehabilitation, despite it being proven 
in many studies to improve both the six-minute walk 
distance and the QOL scores.(19,20) It should be noted as 
well that although studies in pulmonary rehabilitation 
noted improvement in these measures pre- and post-
rehabilitation in the same patients, pre-rehabilitation 
measurements between different patients usually showed 
no statistically significant difference.(21,22)
 In conclusion, the majority of patients presenting 
to our institution had moderate to very severe stages of 
COPD. Although almost all of them were adequately 
treated with inhaled bronchodilators and steroids, the 
uptake rates of LABAs and pulmonary rehabilitation 
are poor. Our National Guidelines has been in existence 
for nearly a decade and needs a review in light of the 
many new recommendations available internationally. 
Compliance to our National Guidelines is unknown, but 
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our data suggests that some aspects of practice do fall 
short of the current recommendations as stipulated by the 
GOLD 2006 Guidelines.
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Appendix 1: St. George’s Respiratory Questionnaire (original English Version)(9)
This	questionnaire	is	designed	to	help	us	learn	much	more	about	how	your	breathing	is	troubling	you	and	how	it	affects	your	life.	
We	are	using	it	to	find	out	which	aspects	of	your	illness	cause	you	most	problems,	rather	than	what	the	doctors	and	nurses	think	
your	problems	are.	Please	read	the	instructions	carefully	and	ask	if	you	do	not	understand	anything.	Do	not	spend	too	long	deciding	
about	your	answers.
Before	completing	the	rest	of	the	questionnaire:
Please	tick	in	one	box	to	show	how	you	describe	your	current	health:	 Very	good	 Good	 Fair	 Poor	 Very	poor
	 ☐	 ☐	 ☐	 ☐	 ☐	
PART 1
Questions about how much chest trouble you have had over the past four weeks. Please tick (✓) one box for each question:
	 	 Most	days	 Several	days		 A	few	days	 Only	with		 Not
	 	 a	week		 a	week	 	a	month	 	 chest			 at
	 	 	 	 	 		 	 infections	 all
1.	 Over	the	past	4	weeks,	I	have	coughed:	 ☐	 ☐	 ☐	 	 ☐		 ☐
2.	 Over	the	past	4	weeks,	I	have	brought	up	phlegm	(sputum):	 ☐	 ☐	 ☐	 	 ☐		 ☐
3.	 Over	the	past	4	weeks,	I	have	had	shortness	of	breath:		 ☐	 ☐	 ☐	 	 ☐		 ☐
4.	 Over	the	past	4	weeks,	I	have	had	attacks	of	wheezing:		 ☐	 ☐	 ☐	 	 ☐		 ☐
5.	 During	the	past	4	weeks,	how	many	severe	or	very	unpleasant	attacks	of	chest	trouble	have	you	had?
	 ☐	>	3	attacks	 ☐	3	attacks		 ☐	2	attacks	 	 ☐	1	attack		 	 ☐	No	attacks
6.	 How	long	did	the	worst	attack	of	chest	trouble	last?	(Go to question 7 if you had no severe attacks)
	 ☐	≥	1	week		 	 ☐	≥ 3	days			 ☐	1–2	days	 	 ☐	<	1	day
7.	 Over	the	past	4	weeks,	in	an	average	week,	how	many	good	days	(with	little	chest	trouble)	have	you	had?
	 ☐	No	good	days	 ☐	1–2	good	days	 ☐	3–4	good	days	 ☐	Nearly	every	day	is	good	 ☐	Every	day	is	good
8.	 If	you	have	a	wheeze,	is	it	worse	in	the	morning?																																			 	 ☐	No								 ☐	Yes
PART 2:	
Section 1
How	would	you	describe	your	chest	condition?
	 The	most	important	problem	I	have	 	 	 ☐
	 Causes	me	quite	a	lot	of	problems	 	 	 ☐
	 Causes	me	a	few	problems	 	 	 ☐
	 Causes	no	problem	 	 	 ☐
If	you	have	ever	had	paid	employment.
	 My	chest	trouble	made	me	stop	work	altogether	 	 	 ☐
	 My	chest	trouble	interferes	with	my	work	or	made	me	change	my	work	 	 ☐
	 My	chest	trouble	does	not	affect	my	work	 	 	 ☐
Section 2:	Questions	about	what	activities	usually	make	you	feel	breathless	these	days.
Please	tick	(✓)	in	each	box	that	applies	to	you	these	days:
	 	 True	 False
	 Sitting	or	lying	still	 ☐	 ☐
	 Getting	washed	or	dressed	 ☐	 ☐
	 Walking	around	the	home	 ☐	 ☐
	 Walking	outside	on	the	level	 ☐	 ☐
	 Walking	up	a	flight	of	stairs	 ☐	 ☐
	 Walking	up	hills	 ☐	 ☐
	 Playing	sports	or	games	 ☐	 ☐
Section 3:	Some	more	questions	about	your	cough	and	breathlessness	these	days.
Please	tick	(✓)	in	each	box	that	applies	to	you	these	days:
	 	 True	 False
	 My	cough	hurts	 ☐	 ☐
	 My	cough	makes	me	tired	 ☐	 ☐
	 I	am	breathless	when	I	talk	 ☐	 ☐
	 I	am	breathless	when	I	bend	over	 ☐	 ☐
	 My	cough	or	breathing	disturbs	my	sleep	 ☐	 ☐
	 I	get	exhausted	easily	 ☐	 ☐
Section 4:	Questions	about	other	effects	that	your	chest	trouble	may	have	on	you	these	days.
Please	tick	(✓)	in	each	box	that	applies	to	you	these	days:
	 	 True	 False
	 My	cough	or	breathing	is	embarrassing	in	public	 ☐	 ☐
	 My	chest	trouble	is	a	nuisance	to	my	family,	friends	or	neighbours	 ☐	 ☐
	 I	get	afraid	or	panic	when	I	cannot	get	my	breath	 ☐	 ☐
	 I	feel	that	I	am	not	in	control	of	my	chest	problem	 ☐	 ☐
	 I	do	not	expect	my	chest	to	get	any	better	 ☐	 ☐
	 I	have	become	frail	or	an	invalid	because	of	my	chest	 ☐	 ☐
	 Exercise	is	not	safe	for	me	 ☐	 ☐
	 Everything	seems	too	much	of	an	effort	 ☐	 ☐
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Section 6: These	are	questions	about	how	your	activities	might	be	affected	by	your	breathing.
Please	tick	(✓)	in	each	box	that	applies	to	you	because	of	your	breathing:
	 	 	 True	 False
	 I	take	a	long	time	to	get	washed	or	dressed	 	 ☐	 ☐
	 I	cannot	take	a	bath	or	shower,	or	I	take	a	long	time	 	 ☐	 ☐
	 I	walk	slower	than	other	people,	or	I	stop	for	rests	 	 ☐	 ☐
	 Jobs	such	as	housework	take	a	long	time,	or	I	have	to	stop	for	rests	 ☐	 ☐
	 If	I	walk	up	one	flight	of	stairs,	I	have	to	go	slowly	or	stop	 	 ☐	 ☐
	 If	I	hurry	or	walk	fast,	I	have	to	stop	or	slow	down	 	 ☐	 ☐
	 My	breathing	makes	it	difficult	to	do	things	such	as	walk	up	hills,	carrying	things	upstairs,	light	 ☐	 ☐
	 gardening	such	as	weeding,	dance,	play	bowls	or	play	golf
	 My	breathing	makes	it	difficult	to	do	things	such	as	carry	heavy	loads,	dig	the	garden	or	shovel	 ☐	 ☐
	 snow,	jog	or	walk	at	5	miles	per	hour,	play	tennis	or	swim	 	 	
	 My	breathing	makes	it	difficult	to	do	things	such	as	very	heavy	manual	work,	run,	cycle,	swim	 ☐	 ☐
	 fast	or	play	competitive	sports	 	
Section 7:		We	would	like	to	know	how	your	chest	usually	affects	your	daily	life.
Please	tick	(✓)	in	each	box	that	applies	to	you	because	of	your	chest	trouble:
	 	 	 True	 False
	 I	cannot	play	sports	or	games	 	 ☐	 ☐
	 I	cannot	go	out	for	entertainment	or	recreation	 	 ☐	 ☐
	 I	cannot	go	out	of	the	house	to	do	the	shopping	 	 ☐	 ☐
	 I	cannot	do	housework	 	 ☐	 ☐
	 I	cannot	move	far	from	my	bed	or	chair	 	 ☐	 ☐
Here	is	a	list	of	other	activities	that	your	chest	trouble	may	prevent	you	doing.	(You	do	not	have	to	tick	these,	they	are	just	to	remind	
you	of	ways	in	which	your	breathlessness	may	affect	you):
•	 Going	for	walks	or	walking	the	dog
•	 Doing	things	at	home	or	in	the	garden
•	 Sexual	intercourse
•	 Going	out	to	church,	pub,	club	or	place	of	entertainment
•	 Going	out	in	bad	weather	or	into	smoky	rooms
•	 Visiting	family	or	friends	or	playing	with	children
•	 Please	write	in	any	other	important	activities	that	your	chest	trouble	may	stop	you	doing:
__________________________________________________________________________________________________________
__________________________________________________________________________________________________________
__________________________________________________________________________________________________________
Now	would	you	tick	in	the	box	(one	only)	which	you	think	best	describes	how	your	chest	affects	you:
	 It	does	not	stop	me	doing	anything	I	would	like	to	do	 	 ☐
	 It	stops	me	doing	one	or	two	things	I	would	like	to	do	 	 ☐
	 It	stops	me	doing	most	of	the	things	I	would	like	to	do	 	 ☐
	 It	stops	me	doing	everything	I	would	like	to	do	 	 ☐
Thank	 you	 for	 filling	 in	 this	 questionnaire.	 Before	 you	 finish	 would	 you	 please	 check	 to	 see	 that	 you	 have	 answered	 all	 the	
questions.
Section 5:	Questions	about	your	medication.	If	you	are	receiving	no	medication,	go	straight	to	Section	6.
Please	tick	(✓)	in	each	box	that	applies	to	you	these	days:
	 	 True	 False
	 My	medication	does	not	help	me	very	much	 ☐	 ☐
	 I	get	embarrassed	using	my	medication	in	public	 ☐	 ☐
	 I	have	unpleasant	side	effects	from	my	medication	 ☐	 ☐
	 My	medication	interferes	with	my	life	a	lot	 ☐	 ☐
Copyright	reserved	:	PW	Jones,		Professor	of	Respiratory	Medicine,	St.	George’s	Hospital	Medical	School,	Jenner	Wing,	Cranmer	Terrace,	London	SW17	ORE,	
UK.	Presentation	is	slightly	modified	to	fit	journal	format.	
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Appendix 2: St. George’s Respiratory Questionnaire (translated to the Malay Language)
Soal Selidik Masalah Pernafasan Hospital St. George (SGRQ)
Soal	selidik	ini	direkabentuk	untuk	membantu	kami	memperoleh	lebih	banyak	maklumat	tentang	bagaimana	masalah	pernafasan	meng-
ganggu	diri	anda	dan	bagaimana	masalah	ini	mempengaruhi	kehidupan	anda.	Kami	akan	menggunakan	maklumat	daripada	soal	selidik	
ini	untuk	mengetahui	sebarang	perkara	tentang	penyakit	anda	yang	menimbulkan	paling	banyak	masalah	kepada	anda.	Kami	tidak	ingin	
tahu	masalah	anda	mengikut	pendapat	doktor	dan	jururawat.
Sila	baca	arahan	dengan	teliti	dan	bertanyalah	jika	ada	perkara	yang	anda	tidak	faham.	
Jangan	mengambil	masa	terlalu	lama	untuk	memikirkan	jawapan	anda.
Sebelum	melengkapkan	soalan-soalan	yang	lain:
Sila	tandakan	(✓)	pada	satu	kotak	sahaja	bagaimana	anda	 Amat	baik	 Baik	 Sederhana	 Teruk	 Amat
menjelaskan	keadaan	kesihatan	anda	pada	masa	ini	:	 	 	 	 	 teruk
	 	 ☐	 ☐	 ☐	 ☐	 ☐
BAHAGIAn 1
Soalan-soalan tentang berapa banyak masalah pernafasan yang telah anda alami sejak 4 minggu yang lalu.
Sila tandakan (✓) pada satu kotak sahaja bagi setiap soalan:
	 	 Kebanyakan	 Beberapa	 Beberapa	 Hanya	jika	 Tiada	
	 	 hari	dalam	 hari	dalam	 hari	dalam	 ada	jangkitan	 langsung	
	 	 seminggu	 seminggu	 sebulan	 paru-paru
1.	 Sejak	4	minggu	lalu,	saya	batuk:	 ☐	 	 ☐	 	 ☐		 ☐	 ☐
2.	 Sejak	4	minggu	lalu,	saya	batuk	berkahak:	 ☐	 	 ☐	 	 ☐		 ☐	 ☐
3.	 Sejak	4	minggu	lalu,	saya	mengalami	sesak	nafas:	 ☐	 	 ☐	 	 ☐		 ☐	 ☐
4.	 Sejak	4	minggu	lalu,	saya	mengalami	serangan	nafas	 ☐	 	 ☐	 	 ☐		 ☐	 ☐	
	 berbunyi	apabila	bernafas:
5.	 Dalam	tempoh	4	minggu	lalu,	berapa	kerapkah	anda	mengalami	serangan	masalah	pernafasan	yang	teruk	atau	sangat	tidak	
	 menyenangkan?
	 Lebih	daripada	3	kali	☐									 	 3	kali	☐								 2	kali	☐										 	1	kali	☐													 Tiada	☐
6.	 Berapa	lamakah	tempoh	masalah	pernafasan	yang	sangat	teruk	itu?
	 (teruskan	menjawab	soalan	7,	jika	anda	tidak	mengalami	masalah	pernafasan	yang	teruk)
	 Satu	minggu	atau	lebih	☐			 3	hari	atau	lebih	☐		 1	atau	2	hari	☐			 Kurang	daripada	1	hari	☐
7.	 Sejak	4	minggu	lalu,	dalam	satu	minggu	yang	biasa,	berapa	harikah	yang	anda	bebas	daripada	masalah	(atau	mengalami	sedikit		
	 masalah	pernafasan)?
	 Tiada	hari	yang	tidak	bermasalah	atau	dengan	sedikit	masalah	 	 	 	 	 	 			☐
	 1	atau	2	hari	tiada	masalah	atau	sedikit	masalah	 	 	 	 	 	 	 			☐
	 3	atau	4	hari		tiada	masalah	atau	dengan	sedikit	masalah	 	 	 	 	 	 			☐
	 Hampir	setiap	hari	tiada	masalah	atau	dengan		sedikit	masalah	 	 	 	 	 	 			☐
	 Setiap	hari	tiada	masalah	atau	dengan	sedikit	masalah	 	 	 	 	 	 			☐
8.	 Jika	anda	mengalami	masalah	nafas	berbunyi,	adakah	masalah	ini	menjadi	lebih	teruk	pada	waktu	pagi	apabila	bangun	dari	tidur?									
	 	 	 	 	 	 	 	 				Tidak	☐														 															Ya	☐
BAHAGIAn 2:	
Seksyen 1
Bagaimana	anda	menjelaskan	keadaan	pernafasan	anda?
	 Masalah	paling	utama	yang	saya	hadapi	 	 ☐
	 Menimbulkan		masalah	yang	agak	banyak	kepada	saya	 	 ☐
	 Menimbulkan	sedikit	masalah	kepada	saya	 	 ☐
	 Tidak	menimbulkan	masalah	kepada	saya	 	 ☐
Sekiranya	anda	pernah	bekerja.
	 Masalah	pernafasan	yang	saya	alami	menyebabkan	saya	berhenti	kerja	 	 ☐
	 Masalah	pernafasan	yang	saya	alami	mengganggu	kerja	saya	atau		 	 ☐
	 menyebabkan	saya	bertukar	kerja
	 Masalah	pernafasan	yang	saya	alami	tidak	menjejaskan	kerja	saya	 	 ☐
Seksyen 2:	Soalan-soalan	tentang	jenis	kegiatan	yang	biasanya	menyebabkan	anda	mengalami	sesak	nafas	sejak	akhir-akhir	ini.
Untuk	setiap	butiran,	sila		tandakan	(✓)		pada	kotak	jika	berkaitan	dengan	diri	anda	sejak	akhir-akhir	ini:
	 	 Ya	 Tidak
	 Duduk	atau	baring	dengan	tenang	 ☐	 ☐
	 Mandi	atau	berpakaian	 ☐	 ☐
	 Berjalan-jalan	di	sekitar	rumah	 ☐	 ☐
	 Bersiar-siar	di	luar	rumah	di	atas	permukaan	rata	 ☐	 ☐
	 Menaiki	satu	tingkat	anak	tangga	 ☐	 ☐
	 Berjalan	menaiki	bukit	 ☐	 ☐
	 Bersukan	atau	bermain	 ☐	 ☐
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Seksyen 3: Beberapa	soalan	lagi	tentang	batuk	atau	kesesakan	bernafas	yang	anda	alami	sejak	akhir-akhir	ini.
Untuk	setiap	butiran,	sila	tandakan	(✓)	pada	kotak	jika	berkaitan	dengan	diri	anda	sejak	akhir-akhir	ini:
	 	 Ya	 Tidak
	 Saya	berasa	sakit	apabila	batuk	 ☐	 ☐
	 Saya	berasa	letih	apabila	batuk	 ☐	 ☐
	 Saya	sesak	nafas	apabila	bercakap	 ☐	 ☐
	 Saya	sesak	nafas	apabila	membongkok	 ☐	 ☐
	 Batuk	atau	pernafasan	mengganggu	tidur	saya	 ☐	 ☐
	 Saya	cepat	terasa	teramat	letih	 ☐	 ☐
Seksyen 4: Soalan-soalan	tentang	kesan	lain	yang		mungkin	disebabkan	oleh	masalah	pernafasan	yang	anda	alami	sejak	akhir-akhir	ini.
Untuk	setiap	butiran,	sila	tandakan	(✓)	pada	kotak	jika	berkaitan	dengan	diri	anda	sejak	akhir-akhir	ini:
	 	 Ya	 Tidak
	 Masalah	batuk	atau	pernafasan	yang	saya	alami	menyebabkan	 ☐	 ☐	
	 saya	berasa	malu	apabila	berada	di	khalayak	ramai
	 Masalah	pernafasan	saya	menyusahkan	keluarga,	kawan-kawan	atau	jiran	 ☐	 ☐
	 Saya	menjadi	takut	atau	panik	jika	saya	sesak	nafas	 ☐	 ☐
	 Saya	berasa	saya	tidak	dapat	mengawal	masalah	pernafasan	saya	 ☐	 ☐
	 Saya	tidak	menjangka	masalah	pernafasan	saya	akan	bertambah	baik	 ☐	 ☐
	 Saya	menjadi	lemah	atau	tidak	berdaya	akibat	masalah	pernafasan	saya	 ☐	 ☐
	 Senaman	tidak	selamat	bagi	saya	 ☐	 ☐
	 Semua	perkara	memerlukan	usaha	yang	banyak	 ☐	 ☐
Seksyen 5: Soalan-soalan	tentang	rawatan	(ubat-ubatan)	yang	diterima.	Jika	anda	tidak	menerima	sebarang	rawatan,	teruskan	men-
jawab	soalan	pada	seksyen	6.
Untuk	setiap	butiran,	sila	tandakan	(✓)	pada	kotak	jika	berkaitan	dengan	anda	sejak	akhir-akhir	ini:
	 	 Ya	 Tidak
	 Ubat-ubatan	yang	diambil	tidak	banyak	membantu	saya	 ☐	 ☐
	 Saya	berasa	malu	apabila	menggunakan	ubat-ubatan	di	khalayak	ramai		 ☐	 ☐
	 Saya	mengalami	kesan	buruk	yang	tidak	menyenangkan	akibat	daripada	ubat-ubatan	saya	 ☐	 ☐
	 Ubat-ubatan	yang	diambil	amat	mengganggu	kehidupan	saya	 ☐	 ☐
Seksyen 6: Berikut	adalah	soalan-soalan	tentang	jenis	kegiatan	yang	anda	lakukan	yang	mungkin	terjejas	akibat	masalah	pernafasan	anda.
Untuk	setiap	butiran,	sila	tandakan	(✓)pada	kotak		jika	berkaitan	dengan	masalah	pernafasan	anda:
																																																																																																																																							 Ya	 Tidak
	 Saya	mengambil	masa	yang	lama	untuk	mandi	atau	berpakaian	 ☐	 ☐
	 Saya	tidak	boleh	berendam	atau	mandi,	atau	saya	mengambil	masa	yang	 ☐	 ☐	
	 terlalu	lama	untuk	berbuat	demikian
	 Saya	berjalan	agak	lambat	jika	dibandingkan	dengan	orang	lain,	atau	saya	perlu	 ☐	 ☐	
	 berhenti	untuk	berehat
	 Kerja	seperti	mengemas	rumah	memakan	masa	yang	terlalu	lama,	atau	saya	terpaksa	 ☐	 ☐	
	 berhenti	untuk	berehat
	 Jika	saya	menaiki	satu	tingkat	anak	tangga,	saya	perlu	berjalan	perlahan-lahan	atau	berhenti	 ☐	 ☐
	 Jika	saya	berjalan	cepat	atau	tergesa-gesa,	saya	harus	berhenti	atau	memperlahankan	 ☐	 ☐	
	 langkah	saya
	 Masalah	pernafasan	menyukarkan	saya		melakukan	kegiatan	seperti	mendaki	bukit,		 ☐	 ☐
	 membawa	barangan	sambil	menaiki	tangga,	kerja	ringan	di	kebun	seperti	merumput,	
	 menari,	bermain	boling	atau	bermain	golf	
	 Masalah	pernafasan	menyukarkan	saya	melakukan	kegiatan	seperti		 ☐	 ☐
	 mengangkat	beban	yang	berat,	mencangkul	di	kebun,	berlari	anak	atau	berjalan
	 cepat	(8	km/jam),	bermain	tenis	atau	berenang	
	 Masalah	pernafasan	saya	menyukarkan	saya	melakukan	kegiatan	seperti		 ☐	 ☐
	 melakukan	kerja	berat,	berlari,	berbasikal,	berenang	deras	atau	menyertai	
	 sukan	yang	memerlukan	stamina	yang	tinggi
Seksyen 7: Kami	ingin	tahu	bagaimana	masalah	pernafasan	yang	anda	alami	biasanya	memberi	kesan	terhadap	kehidupan	harian	anda.	
Untuk	setiap	butiran,	sila	tandakan	(✓)		pada	kotak	jika	berkaitan	dengan	masalah	pernafasan	anda	:
	 	 Ya	 Tidak
	 Saya	tidak	boleh	bersukan	atau	bermain	 ☐	 ☐
	 Saya	tidak	boleh	keluar	untuk	berhibur	atau	berekreasi	 ☐	 ☐
	 Saya	tidak	boleh	keluar	rumah	untuk	membeli-belah	 ☐	 ☐
	 Saya	tidak	boleh	membuat	kerja	rumah	 ☐	 ☐
	 Saya	tidak	boleh	bergerak	jauh	daripada	katil	atau	kerusi	saya		 ☐	 ☐
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Berikut	disenaraikan	beberapa	kegiatan	lain	yang	mungkin	anda	tidak	dapat	 lakukan	disebabkan	oleh	masalah	pernafasan	anda.	
(Anda	tidak	perlu	tandakan	kegiatan	tersebut.	Senarai	kegiatan	ini	hanya	untuk	makluman	anda	bagaimana	kesesakan	nafas	boleh	
mempengaruhi	anda):
•	 Bersiar-siar
•	 Melakukan	perkara	di	dalam	rumah	atau	kebun
•	 Melakukan	perhubungan	seks
•	 Pergi	ke	tempat	ibadat	atau	pergi	ke	tempat	hiburan
•	 Keluar	semasa	keadaan	cuaca	buruk	(hujan,	berjerebu	dsb.)	atau	masuk	ke	dalam	bilik	yang	dipenuhi	asap	rokok
•	 Menziarahi	keluarga	atau	rakan	atau	bermain	bersama	kanak-kanak
•	 Sila	tuliskan	kegiatan	lain	yang	penting	yang	anda	tidak	dapat	lakukan	disebabkan	oleh	masalah	pernafasan	anda:
__________________________________________________________________________________________________________
__________________________________________________________________________________________________________
__________________________________________________________________________________________________________
Akhir	sekali,	tandakan	(✓)	pada	satu	kotak	sahaja,	yang	pada	pendapat	anda	benar-benar	menunjukkan	bagaimana	masalah	pernafasan	
mempengaruhi	anda:
	 Masalah	ini	tidak	menghalang	saya	daripada	melakukan	sebarang	kegiatan	yang	saya	suka	lakukan	 ☐	
	 Masalah	ini	menghalang	saya	daripada	melakukan	satu	atau	dua	kegiatan	yang	saya	suka	lakukan	 ☐	
	 Masalah	ini	menghalang	saya	daripada	melakukan	banyak	kegiatan	yang	saya	suka	lakukan	 ☐	
	 Masalah	ini	menghalang	saya	daripada	melakukan	kesemua	kegiatan	yang	saya	suka	lakukan	 ☐	
	
Terima	 kasih	 kerana	menjawab	 soal	 selidik	 ini.	 	 Sebelum	menamatkan	 soal	 selidik	 ini,	 sila	 pastikan	 anda	 sudah	menjawab	 semua	
soalan.	
